000285584 001__ 285584
000285584 005__ 20240423094335.0
000285584 0247_ $$2pmid$$apmid:37996981
000285584 0247_ $$2ISSN$$a1934-662X
000285584 0247_ $$2ISSN$$a0008-543X
000285584 0247_ $$2ISSN$$a1045-7410
000285584 0247_ $$2ISSN$$a1097-0142
000285584 0247_ $$2ISSN$$a1934-6638
000285584 0247_ $$2doi$$aDOI:10.1002/cncr.35133 
000285584 0247_ $$2doi$$aDOI:10.1002/cncr.35133
000285584 0247_ $$2altmetric$$aaltmetric:156872584
000285584 037__ $$aDKFZ-2023-02446
000285584 041__ $$aEnglish
000285584 082__ $$a610
000285584 1001_ $$0P:(DE-He78)16bd6dc077b72d72e810fd10afeadb09$$aYang, Keyi$$b0$$eFirst author$$udkfz
000285584 245__ $$aDiabetes mellitus in long-term survivors with colorectal, breast, or prostate cancer: Prevalence and prognosis. A population-based study.
000285584 260__ $$aNew York, NY$$bWiley-Liss$$c2024
000285584 3367_ $$2DRIVER$$aarticle
000285584 3367_ $$2DataCite$$aOutput Types/Journal article
000285584 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1713858162_12989
000285584 3367_ $$2BibTeX$$aARTICLE
000285584 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285584 3367_ $$00$$2EndNote$$aJournal Article
000285584 500__ $$a#EA:C071#LA:C071# / 2024 Apr 1;130(7):1158-1170
000285584 520__ $$aPatients with cancer are at increased risk of diabetes mellitus (DM). Previous studies on the prevalence and prognostic impact of DM in cancer survivors were limited by small sample sizes or short follow-up times. We aimed to compare the patient-reported prevalence of DM in long-term cancer survivors (LTCS), who survived 5 years or more after cancer diagnosis, with that in cancer-free controls, and to estimate the mortality risk among LTCS according to DM status.Our population-based cohort comprised 6952 LTCS diagnosed with breast, colorectal, or prostate cancer between 1994 and 2004, recruited in 2008-2011 (baseline), and followed until 2019. A total of 1828 cancer-free individuals served as controls. Multivariable logistic regression was used to compare the prevalence of DM in LTCS and controls, and according to covariates at baseline. Mortality among LTCS according to DM was assessed by Cox proportional hazards regression.A total of 962 (13.8%) LTCS at baseline reported DM. Prevalence of DM in LTCS was not higher than in cancer-free controls, both at baseline (odds ratio, 0.80; 95% CI, 0.66-0.97) and at follow-up (odds ratio, 0.83; 95% CI, 0.67-1.04). Prevalence of DM in LTCS was associated with cancer site, older age, lower education, higher socioeconomic deprivation, higher body mass index, physical inactivity, other comorbidities, and poorer prognosis (adjusted hazard ratio [all-cause mortality] = 1.29; 95% CI, 1.15-1.44).DM in LTCS is prevalent, but not higher than in cancer-free population controls. Cancer survivors with concurrent DM are at a potentially higher risk of death.Cancer and diabetes mellitus (DM) are two serious threats to global health. In our study, prevalence of DM in long-term cancer survivors who survived 5 years or more after cancer diagnosis was not higher than in cancer-free controls. This should not be interpreted as an indication of a lower risk of DM in cancer survivors. Rather, it highlights the potentially poor prognosis in diabetic cancer survivors. Therefore, keeping a continuous satisfactory DM and hyperglycemia management is essential during long-term cancer survivorship.
000285584 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000285584 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000285584 650_7 $$2Other$$acancer survivors
000285584 650_7 $$2Other$$acontrol group
000285584 650_7 $$2Other$$adiabetes mellitus
000285584 650_7 $$2Other$$amortality
000285584 650_7 $$2Other$$aprevalence
000285584 7001_ $$0P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDoege, Daniela$$b1$$udkfz
000285584 7001_ $$0P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aThong, Melissa S Y$$b2$$udkfz
000285584 7001_ $$0P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aKoch-Gallenkamp, Lena$$b3$$udkfz
000285584 7001_ $$0P:(DE-HGF)0$$aWeisser, Linda$$b4
000285584 7001_ $$aBertram, Heike$$b5
000285584 7001_ $$aEberle, Andrea$$b6
000285584 7001_ $$aHolleczek, Bernd$$b7
000285584 7001_ $$aNennecke, Alice$$b8
000285584 7001_ $$aWaldmann, Annika$$b9
000285584 7001_ $$aZeissig, Sylke Ruth$$b10
000285584 7001_ $$aPritzkuleit, Ron$$b11
000285584 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b12$$udkfz
000285584 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b13$$udkfz
000285584 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b14$$eLast author$$udkfz
000285584 773__ $$0PERI:(DE-600)1479932-7$$aDOI:10.1002/cncr.35133$$n7$$p1158-1170$$tCancer$$v130$$x0008-543X$$y2024
000285584 909CO $$ooai:inrepo02.dkfz.de:285584$$pVDB
000285584 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)16bd6dc077b72d72e810fd10afeadb09$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000285584 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000285584 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000285584 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000285584 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000285584 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000285584 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000285584 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000285584 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000285584 9141_ $$y2023
000285584 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000285584 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000285584 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000285584 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000285584 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000285584 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000285584 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000285584 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000285584 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000285584 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000285584 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000285584 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER-AM CANCER SOC : 2022$$d2023-10-21
000285584 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000285584 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000285584 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER-AM CANCER SOC : 2022$$d2023-10-21
000285584 9202_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000285584 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000285584 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000285584 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x2
000285584 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000285584 9200_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000285584 980__ $$ajournal
000285584 980__ $$aVDB
000285584 980__ $$aI:(DE-He78)C071-20160331
000285584 980__ $$aI:(DE-He78)C070-20160331
000285584 980__ $$aI:(DE-He78)C120-20160331
000285584 980__ $$aI:(DE-He78)HD01-20160331
000285584 980__ $$aUNRESTRICTED